These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17532747)

  • 41. Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization.
    Kim DY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Shin SW; Choo SW; Do YS; Rhee JC
    World J Gastroenterol; 2006 Nov; 12(43):6992-7. PubMed ID: 17109521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.
    Yao FY; Hirose R; LaBerge JM; Davern TJ; Bass NM; Kerlan RK; Merriman R; Feng S; Freise CE; Ascher NL; Roberts JP
    Liver Transpl; 2005 Dec; 11(12):1505-14. PubMed ID: 16315294
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand?
    Fujiki M; Aucejo F; Choi M; Kim R
    World J Gastroenterol; 2014 May; 20(18):5308-19. PubMed ID: 24833861
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list.
    Frangakis C; Geschwind JF; Kim D; Chen Y; Koteish A; Hong K; Liapi E; Georgiades CS
    Cardiovasc Intervent Radiol; 2011 Dec; 34(6):1254-61. PubMed ID: 21191590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immediate radical therapy or conservative treatments when meeting the Milan criteria for advanced HCC patients after successful TACE.
    Jiang L; Lei JY; Wang WT; Yan LN; Li B; Wen TF; Xu MQ; Yang JY; Wei YG
    J Gastrointest Surg; 2014 Jun; 18(6):1125-30. PubMed ID: 24664424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective histopathological analysis of hepatocellular carcinoma treated with percutaneous ethanol injection in patients on the waiting list for liver transplantation.
    Castroagudin JF; Delgado M; Martinez SM; Abdulkader I; Potel J; Tome S; Otero E; Varo E
    Transplant Proc; 2005 Apr; 37(3):1477-9. PubMed ID: 15866645
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors determining long-term outcomes of hepatocellular carcinoma within the Milan criteria: liver transplantation versus locoregional therapy: A retrospective cohort study.
    Kim JH; Sinn DH; Gwak GY; Choi GS; Kim JM; Kwon CHD; Joh JW; Kim KY; Kim K; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Medicine (Baltimore); 2016 Aug; 95(35):e4735. PubMed ID: 27583916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Survival after Liver Transplant: Influence of Progression of Disease and of Restoration of the "Milan" Criteria in Patients with Hepato-cellular Carcinoma undergoing Down-staging Procedures.
    Giacomoni A; Di Sandro S; Donadon M; Lauterio A; Belli L; Mangoni I; Mihaylov P; Concone G; De Carlis L
    Hepatogastroenterology; 2015 Jun; 62(140):955-61. PubMed ID: 26902036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation.
    Terzi E; Ray Kim W; Sanchez W; Charlton MR; Schmeltzer P; Gores GJ; Andrews JC; Smyrk TC; Heimbach JK
    Liver Transpl; 2015 Feb; 21(2):248-57. PubMed ID: 25371111
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bridge therapy in hepatocellular carcinoma before liver transplantation: the experience of two Chilean centers.
    Vivanco M; Gabrielli M; Jarufe N; Humeres R; Rios H; Palacios JM; Zapata R; Sanhueza E; Contreras J; Rencore G; Rossi R; Martínez J; Pérez R; Guerra J; Arrese M; Figueroa E; Soza A; Yáñes R; Hepp J
    Transplant Proc; 2010; 42(1):296-8. PubMed ID: 20172335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of Transarterial Chemoembolization to Downstage Hepatocellular Carcinoma Within the Milan Criteria.
    San Miguel C; Muffak K; Triguero J; Becerra A; Villegas T; Nogueras F; Expósito M; Fundora Y
    Transplant Proc; 2015 Nov; 47(9):2631-3. PubMed ID: 26680055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol.
    Sinha J; Mehta N; Dodge JL; Poltavskiy E; Roberts J; Yao F
    Hepatology; 2019 Oct; 70(4):1185-1196. PubMed ID: 30779440
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.
    Doyle A; Gorgen A; Muaddi H; Aravinthan AD; Issachar A; Mironov O; Zhang W; Kachura J; Beecroft R; Cleary SP; Ghanekar A; Greig PD; McGilvray ID; Selzner M; Cattral MS; Grant DR; Lilly LB; Selzner N; Renner EL; Sherman M; Sapisochin G
    J Hepatol; 2019 May; 70(5):866-873. PubMed ID: 30615906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach?
    Sotiropoulos GC; Drühe N; Sgourakis G; Molmenti EP; Beckebaum S; Baba HA; Antoch G; Hilgard P; Radtke A; Saner FH; Nadalin S; Paul A; Malagó M; Broelsch CE; Lang H
    Dig Dis Sci; 2009 Oct; 54(10):2264-73. PubMed ID: 19057997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
    Mehta N; Dodge JL; Grab JD; Yao FY
    Hepatology; 2020 Mar; 71(3):943-954. PubMed ID: 31344273
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
    Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
    Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current controversies surrounding liver transplantation for hepatocellular carcinoma.
    Silva MF; Wigg AJ
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1217-26. PubMed ID: 20594247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria.
    Liu H; Wang ZG; Fu SY; Li AJ; Pan ZY; Zhou WP; Lau WY; Wu MC
    Br J Surg; 2016 Mar; 103(4):348-56. PubMed ID: 26780107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatocellular Carcinoma Progression While on Waiting List for Liver Transplantation.
    Giacomoni A; Concone G; Di Sandro S; Lauterio A; De Carlis L
    Transplantation; 2015 Sep; 99(9):e155-6. PubMed ID: 26308419
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.